EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Heterozygous loss of function variants in IFT140 are associated with polycystic kidney disease

Dinah Clark, Robert Burns, Michelle S Bloom iD, Karen Phaik Har Lim, Lili Li, Lisa M Vincent, Jing Xie, Yuan Xue, Sumit Punj

American Journal of Medical Genetics Part A · 2024

DOI: 10.1002/ajmg.a.63841 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Medical Genetics Part A, 2024. Verfasst von Dinah Clark und 8 weiteren Autor:innen. Beteiligte Einrichtung: Natera, Inc., Austin, Texas, USA. Hauptthemen laut MEDLINE: Heterozygote, Carrier Proteins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natera Inc, Natera.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autosomal dominant polycystic kidney disease (ADPKD) affects 1 in 1000 adults. Most cases result from causative PKD1 or PKD2 variants. HNF1B, GANAB and ALG9 variants are also associated with ADPKD. Recent evidence indicates that monoallelic loss‐of‐function (LoF) IFT140 variants are a cause for non‐syndromic ADPKD. We describe 368 patients with IFT140 LoF variants and a spectrum of phenotypic findings that support the association of IFT140 with PKD. We reviewed patients with an unknown cause for their cystic disease and those with heterozygous LoF IFT140 variants classified as pathogenic or likely pathogenic from a cohort that received genetic testing using a panel of 385 renal disease‐associated genes. IFT140 LoF variants were significantly enriched in patients with cystic disease when compared with those without cystic disease. A cystic phenotype was reported in 223 of the 368 (60.6%) individuals harboring an IFT140 LoF variant, 98% of which had no other identified cause for their cystic disease. Of 122 unique LoF IFT140 variants identified, 56 (46%) were frameshift, 38 (31%) nonsense, 22 (18%) splice site and 6 (5%) exon‐level deletions. Only six IFT140 individuals were reported with end‐stage kidney disease, consistent with observed milder clinical presentations in IFT140‐ related PKD. This study offers further evidence for the involvement of LoF IFT140 variants in PKD, particularly when no additional molecular etiology has been identified.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HeterozygoteCarrier ProteinsHumansFemaleMaleAdultMiddle AgedPolycystic Kidney, Autosomal DominantLoss of Function MutationPhenotypeGenetic Predisposition to DiseaseAdolescentGenetic TestingGenetic Association StudiesAgedYoung AdultPolycystic Kidney Diseases

Stichwörter der Autor:innen

IFT140genetic testingpolycystic kidney diseasevariant

Substanzen

IFT140 protein, humanCarrier Proteins

Autor:innen und Institutionen

  • Natera, Inc., Austin, Texas, USA.
  • Fulgent Genetics, Temple City, California, USA.

ORCID-Profile: Michelle S Bloom

Förderung

  • Natera Inc
  • Natera

Zitieren

APA

Clark, D., Burns, R., Bloom, M. S., Lim, K. P. H., Li, L., Vincent, L. M., Xie, J., Xue, Y., & Punj, S. (2024). Heterozygous loss of function variants in IFT140 are associated with polycystic kidney disease. American Journal of Medical Genetics Part A. https://doi.org/10.1002/ajmg.a.63841

Vancouver

Clark D, Burns R, Bloom MS, Lim KPH, Li L, Vincent LM, et al. Heterozygous loss of function variants in IFT140 are associated with polycystic kidney disease. American Journal of Medical Genetics Part A. 2024. doi:10.1002/ajmg.a.63841

BibTeX
@article{Clark2024,
  author = {Clark, Dinah and Burns, Robert and Bloom, Michelle S and Lim, Karen Phaik Har and Li, Lili and Vincent, Lisa M and Xie, Jing and Xue, Yuan and Punj, Sumit},
  title = {Heterozygous loss of function variants in IFT140 are associated with polycystic kidney disease},
  journal = {American Journal of Medical Genetics Part A},
  year = {2024},
  doi = {10.1002/ajmg.a.63841}
}
Kostenlos starten →